S-309309
S-309309 is an experimental MGAT2 inhibitor developed as an anti-obesity drug by the Japanese company Shionogi.[1][2] Phase II trial results are expected in late 2023.[3]
References[edit]
- ^ S-309309: A Novel Selective Inhibitor of MGAT2 That Exert Potent Anti-Obesity Effect in DIO Mice Kato, Hideaki; Takemoto, Kosuke, MS; Higashino, Kenichi. Obesity; Silver Spring Vol. 30, (Nov 2022): 277-278.
- ^ MGAT2 Inhibition Activates NTS Neurons, Leading to Appetite Suppression and Beneficial Effects Takemoto, Kosuke, MS; Kato, Hideaki; Higashino, Kenichi. Obesity; Silver Spring Vol. 30, (Nov 2022): 278-279.
- ^ Beaney, Abigail (30 June 2023). "Obesity: Six trials to watch over the next 12 months". Clinical Trials Arena. Retrieved 5 December 2023.